A new report from the Government Accountability Office outlines the safety concerns connected with U.S. government oversight of foreign medications and medicinal components. It’s a situation that U.S. Sen. Tom Harkin, chairman of the Health, Education, Labor and Pensions Committee, says Congress needs to address.
The twenty-three corporations on the American Legislative Exchange Council’s (ALEC) board are big spenders in Washington, pressuring federal departments like the Environmental Protection Agency (EPA), targeting congressional initiatives through lobbyists and giving generously to individual members of Congress.
In early August, an obscure measure called Proposition C — which prohibits the government from mandating the purchase of health insurance — passed overwhelmingly in a Missouri referendum and soon became national news. While seen by many legal scholars as a largely symbolic act of defiance, the new statute More…
First of all, take all the weeks of merger negotiations and throw them out the window: It’s looking more and more like the only way the Democrats can pass health care reform — and they must pass health care reform — in the wake of yesterday’s election in More…
Among the chief discrepancies between the House and Senate health reform proposals is a provision of the House bill that would allow states to negotiate directly with pharmaceutical companies for lower drug prices on behalf of their lowest income seniors — those eligible for both Medicare and Medicaid. House leaders, More…
So writes The New York Times, reporting today that the nation’s drug makers are prepping to pay more, under the Democrats’ final health reform bill, than the $80 billion they volunteered in an agreement made with some Democrats earlier in the year.
As the health care bills move
While we’re on the topic of that $80 billion deal struck between Democratic leaders and the nation’s drug makers, it’s worth clarifying how it came to be. Many in the press have reported that the deal originated in the White House, which is perfectly understandable because More…
As we noted, the White House and Senate Democratic leaders yesterday killed legislation that would have significantly lowered prescription drug prices for consumers and the government alike — a proposal that President Obama had endorsed on the campaign trail and many of yesterday’s opposing Democrats had More…
On Monday, The New York Times ran a damning story detailing how the nation’s drug makers are hiking their prices ahead of the reform laws winding their way through Congress. The very next day, some powerful House Democrats called for a closer look, asking the Government Accountability Office More…
It came as little surprise when Senate Finance Committee Chairman Max Baucus (D-Mont.) yesterday moved to kill efforts to lower seniors’ drug costs by squeezing Big Pharma. After all, Baucus earlier in the year had agreed to a controversial deal with the drug lobby, under which More…
rss